Increased expression of telomere length regulating factors TRF1, TRF2 and TIN2 in patients with adult T-cell leukemia

International Journal of Cancer

Volumn 119, Issue 9, 2006, Pages 2090-2097

  Bellon, Marcia ^a   Datta, Abhik ^a   Brown, Megan ^a   Pouliquen, Jean Francois ^b   Couppie, Pierre ^c   Kazanji, Mirdad ^b   Nicot, Christophe ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b Laboratoire de Retrovirologie   (French Guiana)

^c CENTRE HOSPITALIER DE CAYENNE   (French Guiana)

Author keywords

ATL; HTLV I; Leukemia; Telomerase; Telomere; TRF1

Indexed keywords

BINDING PROTEIN; PROTEIN POT1; TELOMERASE; TELOMERE LENGTH REGULATING FACTOR TIN2; TELOMERE LENGTH REGULATING FACTOR TRF1; TELOMERE LENGTH REGULATING FACTOR TRF2; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER GROWTH; CANCER PATIENT; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL LEUKEMIA; TIN2 GENE; TRF GENE;

BASE SEQUENCE; DNA PRIMERS; HL-60 CELLS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JURKAT CELLS; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; TELOMERE; TELOMERE-BINDING PROTEINS; TELOMERIC REPEAT BINDING PROTEIN 1; TELOMERIC REPEAT BINDING PROTEIN 2;

EID: 33748871127     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22026     Document Type: Article

References (50)

1. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-19.
2. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031-5.
3. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The H, El Sabban ME, Hermine O. New therapeutic approaches for adult T-cell leukaemia. Lancet Oncol 2004;5:664-72.
4. + T cell subsets in human T lymphotropic virus type I-infected individuals. J Immunol 1998;161:6674-80.
5. Etoh K, Tamiya S, Yamaguchi K, Okayama A, Tsubouchi H, Ideta T, Mueller N, Takatsuki K, Matsuoka M. Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo. Cancer Res 1997;57:4862-7.
6. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia 2003;17:26-38.
7. Lemoine FJ, Marriott SJ. Accelerated G(1) phase progression induced by the human T cell leukemia virus type 1 (HTLV-I) Tax oncoprotein. J Biol Chem 2001;276:31851-7.
8. Arima N, Tei C. HTLV-I Tax related dysfunction of cell cycle regulators and oncogenesis of adult T cell leukemia. Leuk Lymphoma 2001;40:267-78.
9. de la FC, Santiago F, Chong SY, Deng L, Mayhood T, Fu P, Stein D, Denny T, Coffman F, Azimi N, Mahieux R, Kashanchi F. Overexpression of p21(waf1) in human T-cell lymphotropic virus type 1-infected cells and its association with cyclin A/cdk2. J Virol 2000;74:7270-83.
10. Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT. Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb. Mol Cell Biol 1998;18:3620-32.
11. Cereseto A, Diella F, Mulloy JC, Cara A, Michieli P, Grassmann R, Franchini G, Klotman ME. p53 functional impairment and high p21waf1/cip1 expression in human T-cell lymphotropic/leukemia virus type I-transformed T cells. Blood 1996;88:1551-60.
12. Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J 1996;15:1607-14.
13. Mori N, Fujii M, Cheng G, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Yamamoto N. Human T-cell leukemia virus type I tax protein induces the expression of anti-apoptotic gene Bcl-xL in human T-cells through nuclear factor-κB and c-AMP responsive element binding protein pathways. Virus Genes 2001;22:279-87.
14. Mori N, Yamada Y, Hata T, Ikeda S, Yamasaki Y, Tomonaga M, Yamamoto N. Expression of survival in HTLV-I-infected T-cell lines and primary ATL cells. Biochem Biophys Res Commun 2001;282:1110-13.
15. Nicot C, Astier-Gin T, Guillemain B. Activation of Bcl-2 expression in human endothelial cells chronically expressing the human T-cell lymphotropic virus type I. Virology 1997;236:47-53.
16. Nicot C, Harrod R. Distinct p300-responsive mechanisms promote caspase-dependent apoptosis by human T-cell lymphotropic virus type 1 Tax protein. Mol Cell Biol 2000;20:8580-9.
17. Nicot C, Mahieux R, Takemoto S, Franchini G. Bcl-X(L) is up-regulated by HTLV-I and HTLV-II in vitro and in ex vivo ATLL samples. Blood 2000;96:275-81.
18. Nicot C, Dundr M, Johnson JM, Fullen JR, Alonzo N, Fukumoto R, Princier GL, Derse D, Misteli T, Franchini G. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat Med 2004;10:197-201.
19. Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L, Mulloy JC, Jacobson S, Franchini G. Free major histocompatibility complex class I heavy chain is preferentially targeted for degradation by human T-cell leukemia/lymphotropic virus type 1 p12(I) protein. J Virol 2001;75:6086-94.
20. Evans SK, Lundblad V. Positive and negative regulation of telomerase access to the telomere. J Cell Sci 2000;113 (Part 19):3357-64.
21. Bilaud T, Brun C, Ancelin K, Koering CE, Laroche T, Gilson E. Telomeric localization of TRF2, a novel human telobox protein. Nat Genet 1997;17:236-9.
22. Broccoli D, Smogorzewska A, Chong L, de Lange T. Human telomeres contain two distinct Myb-related proteins, TRF1 and TRF2. Nat Genet 1997;17:231-5.
23. Chong L, van Steensel B, Broccoli D, Erdjument-Bromage H, Hanish J, Tempst P, de Lange T. A human telomeric protein. Science 1995;270:1663-7.
24. Lei M, Podell ER, Cech TR. Structure of human POT1 bound to telomeric single-stranded DNA provides a model for chromosome end-protection. Nat Struct Mol Biol 2004;11:1223-9.
25. Loayza D, de Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature 2003;423:1013-18.
26. Kim SH, Kaminker P, Campisi J. TIN2, a new regulator of telomere length in human cells. Nat Genet 1999;23:405-12.
27. Datta A, Bellon M, Sinha-Datta U, Bazarbachi A, Lepelletier Y, Canioni D, Waldmann TA, Hermine O, Nicot C. 2006 Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence. Blood. [Epub ahead of print].
28. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot JC, Brown M, Kazanji M. Barrett JC, Nicot C. Transcriptional activation of hTERT through the NF-κB pathway in HTLV-I-transformed cells. Blood 2004;104:2523-31.
29. Tsumuki H, Nakazawa M, Hasunuma T, Kobata T, Kato T, Uchida A, Nishioka K. Infection of synoviocytes with HTLV-I induces telomerase activity. Rheumatol Int 2001;20:175-9.
30. Franzese O, Balestrieri E, Comandini A, Forte G, Macchi B, Bonmassar E. Telomerase activity of human peripheral blood mononuclear cells in the course of HTLV type 1 infection in vitro. AIDS Res Hum Retroviruses 2002;18:249-51.
31. Uchida N, Otsuka T, Arima F, Shigematsu H, Fukuyama T, Maeda M, Sugio Y, Itoh Y, Niho Y. Correlation of telomerase activity with development and progression of adult T-cell leukemia. Leuk Res 1999;23:311-16.
32. Franchini G, Fukumoto R, Fullen JR. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int J Hematol 2003;78:280-96.
33. Kubuki Y, Suzuki M, Sasaki H, Toyama T, Yamashita K, Maeda K, Ido A, Matsuoka H, Okayama A, Nakanishi T, Tsubouchi H. Telomerase activity and telomere length as prognostic factors of adult T-cell leukemia. Leuk Lymphoma 2005;46:393-9.
34. Zhou XZ, Lu KP. The Pin2/TRF1 -interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001;107:347-59.
35. Hatta Y, Yamada Y, Tomonaga M, Koeffler HP. Extensive analysis of the retinoblastoma gene in adult T cell leukemia/lymphoma (ATL). Leukemia 1997;11:984-9.
36. Hatta Y, Hirama T, Miller CW, Yamada Y, Tomonaga M, Koeffler HP. Homozygous deletions of the p15 (MTS2) and p16 (CDKN2/MTS1) genes in adult T-cell leukemia. Blood 1995;85:2699-704.
37. Yasunaga J, Taniguchi Y, Nosaka K, Yoshida M, Satou Y, Sakai T, Mitsuya H, Matsuoka M. Identification of aberrantly methylated genes in association with adult T-cell leukemia. Cancer Res 2004;64:6002-9.
38. Engelhardt M, Albanell J, Drullinsky P, Han W, Guillem J, Scher HI, Reuter V, Moore MA. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma. Clin Cancer Res 1997;3:1849-57.
39. Nilsson P, Mehle C, Remes K, Roos G. Telomerase activity in vivo in human malignant hematopoietic cells. Oncogene 1994;9:3043-8.
40. Broccoli D, Young JW, de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc Natl Acad Sci USA 1995;92:9082-6.
41. van Steensel B, de Lange T. Control of telomere length by the human telomeric protein TRF1. Nature 1997;385:740-3.
42. Ohyashiki K, Iwama H, Yahata N, Tauchi T, Kawakubo K, Snimamoto T, Ohyashiki JH. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 2001;42:291-9.
43. Ladetto M, Compagno M, Ricca I, Pagano M, Rocci A, Astolfi M, Drandi D, di Celle PF, Dell'Aquila M, Mantoan B, Vallet S, Pagliano G, et al. Telomere length correlates with histopathogenesis according to the germinal center in mature B-cell lymphoproliferative disorders. Blood 2004;103:4644-9.
44. Grabowski P, Hultdin M, Karlsson K, Tobin G, Aleskog A, Thunberg U, Laurell A, Sundstrom C, Rosenquist R, Roos G. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005;105:4807-12.
45. Matsutani N, Yokozaki H, Tahara E, Tahara H, Kuniyasu H, Haruma K, Chayama K, Yasui W, Tahara E. Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas. Int J Oncol 2001;19:507-12.
46. Yokota T, Suda T, Igarashi M, Kuroiwa T, Waguri N, Kawai H, Mita Y, Aoyagi Y. Telomere length variation and maintenance in hepatocarcinogenesis. Cancer 2003;98:110-18.
47. Karlseder J, Broccoli D, Dai Y, Hardy S, de Lange T. p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science 1999;283:1321-5.
48. Karlseder J, Smogorzewska A, de Lange T. Senescence induced by altered telomere state, not telomere loss. Science 2002;295:2446-9.
49. Ye JZ, Donigian JR, van Overbeek M, Loayza D, Luo Y, Krutchinsky AN, Chait BT, de Lange T. TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres. J Biol Chem 2004;279:47264-71.
50. Kim SH, Beausejour C, Davalos AR, Kaminker P, Heo SJ, Campisi J. TIN2 mediates functions of TRF2 at human telomeres. J Biol Chem 2004;279:43799-804.